Hattori T, Ueda T, Sato Y, Chikuie N, et al. Baseline eosinophil proportion is a useful predictor of immune-related adverse events following immune checkpoint inhibitor treatment for recurrent metastatic head and neck cancer. Acta Otolaryngol 2024 Sep 20:1-9. doi: 10.1080/00016489.2024.2390084.
PMID: 39302314